In this Phase 3 trial, Dupixent added to standard-of-care antihistamines nearly doubled reduction in itch and urticaria activity scores compared to standard-of-care alone at 24 weeks in biologic-naïve patients uncontrolled on antihistamines Data reinforce the potential of targeting IL-4 and IL-13, key drivers of type 2 inflammation, in this complex chronic disease Regeneron Pharmaceuticals, Inc….

Aquest contingut és només per a membres de SUBSCRIPCIÓ GRATUÏTA.
Login Unir-se ara

QUÈ TREURE D'AQUEST ARTICLE:

In this Phase 3 trial, Dupixent added to standard-of-care antihistamines nearly doubled reduction in itch and urticaria activity scores compared to standard-of-care alone at 24 weeks in biologic-naïve patients uncontrolled on antihistamines Data reinforce the potential of targeting IL-4 and IL-13, key drivers of type 2 inflammation, in this complex chronic disease Regeneron Pharmaceuticals, Inc….
.
Aquest contingut és només per a membres de SUBSCRIPCIÓ GRATUÏTA.